KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Alnylam Pharmaceuticals (ALNY) Accumulated Depreciation & Amortization (2017 - 2025)

Alnylam Pharmaceuticals' Accumulated Depreciation & Amortization history spans 14 years, with the latest figure at $322.7 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 19.36% year-over-year to $322.7 million; the TTM value through Dec 2025 reached $322.7 million, up 19.36%, while the annual FY2025 figure was $322.7 million, 19.36% up from the prior year.
  • Accumulated Depreciation & Amortization reached $322.7 million in Q4 2025 per ALNY's latest filing, up from $270.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $322.7 million in Q4 2025 to a low of $140.4 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $226.0 million, with a median of $223.1 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 34.57% in 2021, then increased 19.36% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $140.4 million in 2021, then grew by 23.53% to $173.4 million in 2022, then rose by 28.61% to $223.1 million in 2023, then increased by 21.2% to $270.4 million in 2024, then increased by 19.36% to $322.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Accumulated Depreciation & Amortization are $322.7 million (Q4 2025), $270.4 million (Q4 2024), and $223.1 million (Q4 2023).